Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant

Journal of Medical Virology

Volumn 81, Issue 10, 2009, Pages 1760-1772

  Cote, Paul J ^a   Butler, Scott D ^b   George, Andrea L ^b   Fairman, Jeffery ^c   Gerin, John L ^a   Tennant, Bud C ^b   Menne, Stephan ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Juvaris BioTherapeutics Inc   (United States)

Author keywords

Adjuvant; Cationic liposome DNA complexes; Hepatitis B virus; Vaccine; Woodchuck

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CATIONIC LIPOSOME PLUS NONCODING PLASMID DNA COMPLEX; CYTOKINE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE SURFACE MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HEPATITIS B; HEPATITIS VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; WOODCHUCK;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; DNA; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS, WOODCHUCK; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LIPOSOMES; MARMOTA; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS VIRUS;

EID: 69949155082     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21566     Document Type: Article

References (60)

1. Bertoletti A, Ferrari C. 2003. Kinetics of the immune response during HBV and HCV infection. Hepatology 38:4-13. (Pubitemid 36775788)
2. Brignone C, Grygar C, Marcu M, Perrin G, Triebel F. 2007. IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: A single blind randomised controlled phase I study. J Immune Based Ther Vaccines 5:5. (Pubitemid 46605666)
3. Celis E, Ou D, Otvos L, Jr. 1988. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 140:1808-1815.
4. Chisari FV. 2000. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B. Am J Pathol 156:1117-1132.
5. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathology. Springer Semin Immunopathol 17:261-281.
6. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. 2004. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study. J Clin Immunol 24:693-701. (Pubitemid 40933121)
7. Cote PJ, Gerin JL. 1995. In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: Implications for modeling immunity and therapy in hepatitis B virus infection. Hepatology 22:687-699.
8. Cote PJ, Roneker C, Cass K, Schodel F, Peterson D, Tennant B, De Noronha F, Gerin J. 1993. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol 6:161-169. (Pubitemid 23244877)
9. Cote PJ, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, Purcell RH, Tennant BC, Gerin JL. 2000a. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 31:190-200.
10. Cote PJ, Toshkov I, Bellezza C, Ascenzi M, Roneker C, Ann Graham L, Baldwin BH, Gaye K, Nakamura I, Korba BE, Tennant BC, Gerin JL. 2000b. Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: Increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection. Hepatology 32:807-817. (Pubitemid 30744280)
11. Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel ML. 1999. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15-26. (Pubitemid 29293912)
12. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160:870-876. (Pubitemid 28049329)
13. Deulofeut H, Iglesias A, Mikael N, Bing DH, Awdeh Z, Yunis J, Marcus-Bagley D, Kruskall MS, Alper CA, Yunis EJ. 1993. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol Immunol 30:941-948. (Pubitemid 23220994)
14. Dow SW, Elmslie RE, Fradkin LG, Liggitt DH, Heath TD, Willson AP, Potter TA. 1999a. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 10:2961-2972.
15. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. 1999b. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163:1552-1561.
16. Dow SW, Schwarze J, Heath TD, Potter TA, Gelfand EW. 1999c. Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum Gene Ther 10:1905-1914.
17. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, Petit MA, Fiaccadori F. 1990. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145:3442-3449.
18. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, Pilli M, Fowler P, Giuberti T, Chisari FV, et al. 1991. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88:214-222.
19. Ferrari C, Cavalli A, Penna A, Valli A, Bertoletti A, Pedretti G, Pilli M, Vitali P, Neri TM, Giuberti T, et al. 1992. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 103:255-263.
20. Fessard C, Riche O, Cohen JH. 1988. Intramuscular versus subcutaneous injection for hepatitis B vaccine. Vaccine 6:469.
21. Freimark BD, Blezinger HP, Florack VJ, Nordstrom JL, Long SD, Deshpande DS, Nochumson S, Petrak KL. 1998. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: Cationic lipid complexes. J Immunol 160:4580-4586. (Pubitemid 28217318)
22. Ganem D. 1996. Hepadnaviridae: The virus and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology, 3rd ed. Philadelphia, PA:Lippincott-Raven. pp 2703-2737.
23. Gerin JL, Faust RM, Holland PV. 1975. Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. J Immunol 115:100-105.
24. Gerin JL, Tennant BC, Popper H, Tyeryar FJ, Purcell RH. 1986. The woodchuck model of hepadnavirus infection and disease. In: Brown F, Chanock R, Lerner R, editors. Vaccines 86: New approaches to immunization. Cold Spring Harbor, NY:Cold Spring Harbor Laboratory. pp 383-386.
25. Gowen BB, Fairman J, Smee DF, Wong MH, Jung KH, Pace AM, Heiner ML, Bailey KW, Dow SW, Sidwell RW. 2006. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 69:165-172. (Pubitemid 43247337)
26. Gujar SA, Jenkins AK, Guy CS, Wang J, Michalak TI. 2008. Aberrant lymphocyte activation precedes delayed virus-specific T-cell response after both primary infection and secondary exposure to hepadnavirus in the woodchuck model of hepatitis B virus infection. J Virol 82:6992-7008. (Pubitemid 351977720)
27. Gursel I, Gursel M, Ishii KJ, Klinman DM. 2001. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167:3324-3328. (Pubitemid 32852574)
28. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, Levitt D, Nest GV, Gennevois D, Eiden JJ. 2006. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24:20-26. (Pubitemid 41721097)
29. Honorati MC, Dolzani P, Mariani E, Piacentini A, Lisignoli G, Ferrari C, Facchini A. 1997. Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 112:2017-2027. (Pubitemid 27240789)
30. Hornbuckle WE, Graham ES, Roth L, Baldwin BH, Wickenden C, Tennant BC. 1985. Laboratory assessment of hepatic injury in the woodchuck (Marmota monax). Lab Anim Sci 35:376-381. (Pubitemid 15014301)
31. Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, Frosner G, Will H, Pape GR. 1995. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 69:3358-3368.
32. Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL. 2000. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165-1175. (Pubitemid 30233243)
33. Lohr HF, Weber W, Schlaak J, Goergen B, Meyer zum Buschenfelde KH, Gerken G. 1995. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis Be-minus hepatitis B virus mutants. Hepatology 22:61-68.
34. Luxembourg A, Hannaman D, Wills K, Bernard R, Tennant BC, Menne S, Cote PJ. 2008. Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens. Vaccine 2:1-14.
35. Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, Rowlands DJ, Eddleston AL, Naoumov NV, Williams R. 1995. Induction of Thelper cell response to hepatitis B core antigen in chronic hepatitis B: A major factor in activation of the host immune response to the hepatitis B virus. Hepatology 22:1040-1049.
36. Menne S, Cote PJ. 2004. Measurement of cell-mediated immune response in woodchucks. Methods Mol Med 96:27-36.
37. Menne S, Cote PJ. 2007. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 13:104-124. (Pubitemid 46165467)
38. Menne S, Maschke J, Tolle TK, Lu M, Roggendorf M. 1997. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol 71:65-74. (Pubitemid 26412266)
39. Menne S, Maschke J, Lu M, Grosse-Wilde H, Roggendorf M. 1998. T-cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol 72:6083-6091. (Pubitemid 28283398)
40. Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. 2002a. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 76:1769-1780. (Pubitemid 34094624)
41. Menne S, Wang Y, Butler SD, Gerin JL, Cote PJ, Tennant BC. 2002b. Real-time polymerase chain reaction assays for leukocyte CD and cytokine mRNAs of the Eastern woodchuck (Marmota monax). Vet Immunol Immunopathol 87:97-105. (Pubitemid 34621436)
42. Menne S, Cote PJ, Butler SD, Toshkov IA, Gerin JL, Tennant BC. 2007a. Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. Hepatology 45:614-622. (Pubitemid 46450612)
43. Menne S, Tennant BC, Gerin JL, Cote PJ. 2007b. Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein. J Virol 81:10614-10624. (Pubitemid 47463335)
44. Milich DR, McLachlan A, Thornton GB, Hughes JL. 1987. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329:547-549. (Pubitemid 17124776)
45. Nakamura I, Nupp JT, Cowlen M, Hall WC, Tennant BC, Casey JL, Gerin JL, Cote PJ. 2001. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: Chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 33:439-447. (Pubitemid 32119034)
46. Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH. 2006. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. Intervirology 49:144-151. (Pubitemid 43131546)
47. Pead PJ. 1986. Immune responses to hepatitis B vaccination in hospital staff. Biomed Pharmacother 40:251-253. (Pubitemid 17203015)
48. Pead PJ, Saeed AA. 1986. Hepatitis B vaccination: Effect of re-vaccination and injection site in suboptimal responders. Eur J Epidemiol 2:240-241.
49. Rehermann B. 2000. Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury. J Exp Med 191:1263-1268. (Pubitemid 30227115)
50. Sellins K, Fradkin L, Liggitt D, Dow S. 2005. Type I interferons potently suppress gene expression following gene delivery using liposome-(-)DNA complexes. Mol Ther 12:451-459. (Pubitemid 41150130)
51. Sorkhi H, Dooki MR, Ebrahimnejad MS. 2006. Low-dose intradermal and subcutaneous versus intramuscular hepatitis B vaccination in primary non-responding hemodialysis patients. J Med Assoc Thai 89:1648-1653. (Pubitemid 44747535)
52. Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL. 2004. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127:S283-S293. (Pubitemid 39423398)
53. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, Chang TH, Chen DS. 1992. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 89:87-96.
54. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. 2007. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 21:113-120. (Pubitemid 46266155)
55. Wang Y, Menne S, Jacob JR, Tennant BC, Gerin JL, Cote PJ. 2003. Role of type 1 versus type 2 immuneresponses in liver during the onset of chronic woodchuck hepatitis virus infection. Hepatology 37:771-780. (Pubitemid 36397387)
56. Wang Y, Menne S, Baldwin BH, Tennant BC, Gerin JL, Cote PJ. 2004. Kinetics of viremia and acute liver injury in relation to outcome of neonatal woodchuck hepatitis virus infection. J Med Virol 72:406-415. (Pubitemid 38133981)
57. Weeratna R, Comanita L, Davis HL. 2003. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol 81:59-62. (Pubitemid 36237793)
58. Whitmore M, Li S, Huang L. 1999. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 6:1867-1875. (Pubitemid 29531282)
59. Whitmore MM, Li S, Falo L, Jr., Huang L. 2001. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 50:503-514. (Pubitemid 34028283)
60. Zhu N, Liggitt D, Liu Y, Debs R. 1993. Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211. (Pubitemid 23265397)